{"filing":{"accession_number":"0001193125-26-336867","cik":"0001528115","ticker":"ANNX","company_name":"Annexon, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d159969d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526336867/d159969d8k.htm"},"events":[{"id":25568,"run_id":23207,"accession_number":"0001193125-26-336867","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Annexon disclosed positive interim clinical trial results from the FORWARD study showing rapid, clinically meaningful improvements in all ten tanruprubart-treated GBS patients within days, with data expected to support a BLA submission targeted for Q4 2026. While this is a clinical milestone for a biopharmaceutical company's lead investigational therapy, it does not fit neatly into earnings_release (no financial results disclosed), material_litigation, or other specific event types. The disclosure centers on a material operational/clinical development milestone that would affect investor assessment of the company's regulatory pathway and commercial prospects, making operational_other the most appropriate classification.","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26440,"accession_number":"0001193125-26-336867","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Annexon disclosed positive interim clinical trial results from the FORWARD study showing rapid, clinically meaningful improvements in all ten tanruprubart-treated GBS patients within days, with data expected to support a BLA submission targeted for Q4 2026. While this is a clinical milestone for a biopharmaceutical company's lead investigational therapy, it does not fit neatly into earnings_release (no financial results disclosed), material_litigation, or other specific event types. The disclosure centers on a material operational/clinical development milestone that would affect investor assessment of the company's regulatory pathway and commercial prospects, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:00.673558+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26440,"accession_number":"0001193125-26-336867","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Annexon disclosed positive interim clinical trial results from the FORWARD study showing rapid, clinically meaningful improvements in all ten tanruprubart-treated GBS patients within days, with data expected to support a BLA submission targeted for Q4 2026. While this is a clinical milestone for a biopharmaceutical company's lead investigational therapy, it does not fit neatly into earnings_release (no financial results disclosed), material_litigation, or other specific event types. The disclosure centers on a material operational/clinical development milestone that would affect investor assessment of the company's regulatory pathway and commercial prospects, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:00.673558+00:00","company_name":"Annexon, Inc.","ticker":"ANNX","filing_date":"2026-08-06"}]}